Verona Pharma PLC (VRNA)
37.86
-0.99
(-2.55%)
USD |
NASDAQ |
Nov 21, 16:00
37.93
+0.07
(+0.18%)
After-Hours: 20:00
Verona Pharma EPS Diluted (Quarterly): -0.56 for Sept. 30, 2024
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | -0.56 |
| June 30, 2024 | -0.88 |
| March 31, 2024 | -0.32 |
| December 31, 2023 | -0.24 |
| September 30, 2023 | -0.16 |
| June 30, 2023 | -0.08 |
| March 31, 2023 | -0.24 |
| December 31, 2022 | -0.08 |
| September 30, 2022 | -0.24 |
| June 30, 2022 | -0.32 |
| March 31, 2022 | -0.40 |
| December 31, 2021 | -0.40 |
| September 30, 2021 | 0.16 |
| June 30, 2021 | -0.40 |
| March 31, 2021 | -0.40 |
| December 31, 2020 | -0.4287 |
| September 30, 2020 | -0.40 |
| Date | Value |
|---|---|
| June 30, 2020 | -0.64 |
| March 31, 2020 | -0.96 |
| December 31, 2019 | -0.768 |
| September 30, 2019 | -0.944 |
| June 30, 2019 | -0.8618 |
| March 31, 2019 | -0.5322 |
| December 31, 2018 | -0.2405 |
| September 30, 2018 | -0.2293 |
| June 30, 2018 | 0.0607 |
| March 31, 2018 | -1.626 |
| December 31, 2017 | -0.665 |
| September 30, 2017 | -0.9324 |
| June 30, 2017 | -0.3747 |
| March 31, 2017 | -0.3693 |
| December 31, 2016 | -0.1047 |
| September 30, 2016 | -0.615 |
| June 30, 2016 | -0.4271 |
Earnings per Share Definition
Earnings per share measures the total net income / average shares outstanding during income period. There are a few variations to earnings per share that are listed including "EPS Basic", "EPS Diluted", "Normalized Basic EPS", and "Normalized Diluted EPS". Each of these metrics are dependent on which earnings and shares outstanding metrics are used. Basic and Diluted EPS differ in that diluted shares are the amount of shares outstanding after all convertible securities, options, and warrants are exercised. Normalized EPS allows does not include one-time expenses.
EPS Diluted (Quarterly) Range, Past 5 Years
-0.96
Minimum
Mar 2020
0.16
Maximum
Sep 2021
-0.3878
Average
-0.40
Median
Sep 2020
EPS Diluted (Quarterly) Benchmarks
| Biodexa Pharmaceuticals PLC | -- |
| TC BioPharm (Holdings) PLC | -27.90 |
| Adaptimmune Therapeutics PLC | -0.06 |
| NuCana PLC | -3.785 |
| Autolus Therapeutics PLC | -0.31 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -42.96M |
| Revenue (Quarterly) | 5.624M |
| Total Expenses (Quarterly) | 44.68M |
| Enterprise Value | 2.882B |
| Gross Profit Margin (Quarterly) | 90.34% |
| Profit Margin (Quarterly) | -763.9% |
| Earnings Yield | -5.28% |
| Normalized Earnings Yield | -5.264 |